### INSIST! NON-SMALL CELL LUNG CANCER

Program Resource Guide



### **Insist on Better Lung Cancer Care**

- Ensure you have undergone biomarker testing prior to choosing treatment.
- Consider a second opinion and/or a consult with a lung cancer specialist.
- Include a friend or family member in your appointments.
- Always speak up and ask questions. You have a voice in YOUR care.



## **Stages of Lung Cancer**

- Stage I: The lung cancer is located only in the lungs. It has not spread to lymph nodes.
- Stage II: The lung cancer may or may not have spread into the nearest lymph nodes.
- Stage III: The cancer is in the lungs and in the lymph nodes located in the middle of the chest.
- Stage IV: The lung cancer has spread beyond the lungs to other areas of the body.

## **Advocating for a Precise Diagnosis**

- Confirm lung cancer diagnosis.
- Know lung cancer stage.
- Understand treatment options.
- Ensure essential testing has taken place.
- Discuss which option is best for your lung cancer.

# **Lung Cancer Driver Mutations**

Driver mutations can determine whether a particular targeted therapy may be effective. Common driver mutations include:

- ALK
- ROS1
- BRAF
- NTRK
- EGFR

### **Lung Cancer Resources**

- CancerGrace
- Cancer Support Community
- EGFR Resisters
- Lung Cancer Initiative of North Carolina
- International Association for the Study of Lung Cancer (IASCLC)
- National Comprehensive Cancer Center Network (NCCN)

#### **Glossary Terms**

**Biopsy:** Removal of tissue from a specific area of the body for further examination.

**Biomarker Testing (molecular testing):** Laboratory testing that identifies certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. In cancer, it may also be used to evaluate treatment or to make a prognosis.

**Immunotherapy:** Type of therapy that harnesses one's own immune system to help the body fight cancer, infection, and other diseases.

**PD-L1 Expression:** PD-L1 is a receptor expressed on the surface of T cells. The presence of PD-L1 indicates that a lung cancer patient may respond to immunotherapy.

**Targeted Therapy:** A type of personalized medicine that works by blocking specific mutations and by preventing cancer cells from growing and dividing, without affecting normal cells.

Insist! Non-Small Cell Lung Cancer is brought to you by the Patient Empowerment Network. It is made possible through support from Amgen and generous donations from people like you.



question@powerfulpatients.org

www.powerfulpatients.org



@power4patients